Conclusion
The results suggested that when treating UCB in patients with CP, combination therapy with EPO may be more effective and lasts longer than two years without harmful effects, especially in patients with severe impairments. Greater numbers of cells may lead to better outcomes. Further studies will be necessary to show the efficacy of multiple dosages with shorter intervals.